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T he communicatio n in tlu. ·s issue of The jollmn/ by Kuivaniemi and colleagues (p. 352) [1] about the molecular basis for m.is-splicing of the type III coll a-gen gene (COL3A1) in a fumiJy with Ehlers-DanJos syndrom e (EDS) type IV reminds us of a disorder 
whose detmatologic findings are more curiosity than concern but 
w hose systemic compli ca tions ca n be, and genera lly are, lethal. 
Tlus condition was first considered as a variant form of EDS by 
Barabas [2], who noted the bruising and small -joint la"-':ity, and 
thought it similar to th e condition described separately at the turn 
of the century by Ehlers [3) and by Danlos [4). As McKusick [5) has 
pointed out, a lthough the first formal medical description of EDS 
probably was by Tschemogubow [6), people with startling skin 
hyperextensibility were known before the n. Beighton [7], in for-
malizing a catalogue of individuals with EDS, designated the 
ecchymotic variety as EDS type IV and added a fifth type, winch he 
thought to be X -linked. Biochemical studies subsequently disti.n-
guished a recessively inherited form that results from lysyl hydrox-
ylase deficiency (E DS type VI) [8], three form s that result f'i-om 
defects in processing the amino-terminal end of the type I procol-
lagen molecules (EDS type VII) [9-14], a disorder that results from 
mutations in a copper-tran sport gene and is allelic to M enkes 
syndrome (EDS type IX) [15 ,16), and a last varie ty that may result 
from defects in fibronectin (EDS type X) [17]. 
EDS type IV is almost certainly the "acrogeria" described by 
Gottron [18) in the Europe:m literature, and the disorder re ported 
earlier by Sack [19]; in some places, EDS type IV has become 
known as the "vascular-ecchymotic " form of EDS or the Sack-
Barabas type. 
EDS type IV was the second of the disorders of collagen mole-
cules to gain a biochemical identity when, through the collaborative 
efforts of George Martin at the NIH, Victor M cKusick at Johns 
Hopkins University, and their joint fe llow, F. Mi ch ael Pope, 
working at th e NIH, it was recognized that ''Patients with Ehl ers-
DanJos syndrome type fV lack type IH collagen" [20], a title that to 
tllis day leads to the confusion , "Is it type IJI collagen iJ1 EDS type 
IV or type IV collagen in EDS type III?" T he biochemical studies by 
Pope and his colleagues suggested that in one famiJy EDS type IV 
might be a recessive ly inherited disorder L21], an issue raised again 
by the family structure reported by Kuivaniemi and colleagues . 
The rarity of EDS type IV as an identified entity, the sporadic 
nature of the disorder in the majority of f.,milies initially identified, 
and the apparent alterations in type III collagen metabolism by cells 
from the parent of the initial proband studied by Pope and 
colleagues led them to think that EDS type IV was a recessively 
inherited disorder. Since then, both from family studies and mo-
lecular studies, it ha s become clear that EDS type IV is a dominantly 
inherited disorder in which only on e of two COL3A1 alleles 
harbors mutations [22]. In a small set of families , one asymptomatic 
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parent is a mosaic for the mutation, so that h e or she has some cells, 
generally the minority, in which there is one mutant allele and one 
normal alle le, and others in w hich there are only normal all e les 
[23]. If, during embryonic development following the time of the 
mutation event, one or more of th e mutation-bearing cells contrib-
ute to the germ line, offspring may be heterozygous for the 
deleterious alJele and may develop the clinica] fea tures ofE DS type 
IV. 
The de rmatologic manifestations ofEDS type IV are variable. ln 
some people, acrogeria .is striking, and the aged appearance of the 
skin, particuJarly of the hands and fe e t, generates comment al-
though not always medical referral. When examined, those people 
have thin, atrophic-appearing skin over aJmost th e entire body, 
readily apparent venous patterning, and a tigh t parchment-like 
character to the skin of the face [24] . Bruising is sometimes so 
striking that hematologic evaluation is undertaken with the usuaJ 
result that no abnormality is identified. E lastosis perforans serpigi-
nosa may be a clue to the diagnosis. 
Examination of a skin biopsy by routine techniques is generally 
non-diagnostic, al though the skin may seem very tlun and collagen 
bundles may be sm all [25]. If the examination is extended to the 
e lectron microscope, a characteristic pic ture emerges: the skin is 
thin, the collagen fibrils are small , and the de rmal fibrobl as ts at·e 
pa cked with dilated rough endop lasmic reticulum that contains 
proteinaceous material (the abnormal type III procollagen mole-
cules) . Such fmdings led Laurent and Agach e to ask, m ore than 20 
years ago, "L'acrogeria, est-elle une maladie du fibrobla sts?" [26]. 
Now. more than ever, the answer is yes and no; tl1e primary d efect 
is in the COL3A1 gene but the e ffec ts of the mutations ar e to 
interfere with secretion of almost all the type III procollagen 
molecules being synthesized , so that tl1e secre tory pathway be-
comes packed with useless proteins. Individua ls with this " classic" 
clinica.l presentation of EDS type IV are very likely to have 
mutations that res ide within the region of th e COL3A1 gene that 
encodes the carboxy l-terminal end of the triple helical domain of 
the protein. T he " acrogeric " presentation is, however , not the 
most common one. ln many affe cted individuals, a.lthough bruising 
may be increased, skin often seems almost norma.!; th e thinning of 
skin over the fa ce and " acrogeri c" chat·acter of skin is minimal. 
Even electronmicroscopic studies are not as dmmatic. Cells often 
have little or no detectable storage, and collagen fibri ls may be 
quite variable in diameter , a fea ture that may be missed unless an 
experienced microscopist does the evaluation. 
In som e individuals the cljnical dia!,rnosis is quite apparent, but in 
others it may not be considered until a complication ensues . In 
some famili es the condition has persisted through several gen era-
tions before an affected individual comes to medica l attention and 
the diagnosis is considered. How docs this happen ? First, the 
disorder is rare to uncommon. Current estimates of the prevalence 
vary fi·om 1/50,000 to l /5 00,000. T he first estimate assumes that 
the frequ en cy of mutations in the COL3A 1 gene is about the same 
as in the type f collagen genes that result in osteogenesis imperfecta. 
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T he second estimate is derived from the approximate number seen 
by Pope and hi s colleagues in Great Britain. Second, the pleiotwpic 
effect of mutations in the COL3A 1 gene (that is, the effect on 
multipl e organ systems) may obscure the diagnosis. Finally, knowl-
edge about th e disorder is not widespread. 
Individuals w ith EDS type IV have a decreased life span. ln our 
study of more than 200 people known to be affected with the 
condition, ascertained through our studies in Seattle, we have 
found tha t about haLf died before reachi ng 40 years of age. 
A lthough un common, li fe-span into the 50s and 60s does occur. 
With many people who have EDS type IV , there is little or no 
warning of the catastrophic arterial rupture, colon rupture, or 
ruptu.re of the uterus during pregnancy that can lead to death . ln 
about half of those ins tances, a detailed family history unearths one 
or more re la tives with a similar in cident and i11 some families tlu·ee 
or more generations of affected individuals can be identified, in 
retrospect. The ex tent of the physical findings and presentations of 
one individual w e studied illustrate the varied effects of mutations 
in the C OL3A l gene. He experien ced rupture of the sma ll intestin e 
at age 6 years, hem orrhage into the ··ight proximal tibial epiphys is 
at age 12, bilateral corneal transplantation for keratoconus at age 22 
yea rs, a left cerebral stroke from aneurysmal invo lve ment of one of 
the cerebral artm;es at age 27, and rupture of the right brachial 
artery while bowling at age 29 before the diagnosis was considered. 
Until that point, equivocally abnom1al clotting fa ctor stud ies w ere 
thought to be consistent with the diagnosis of a "variant form of 
hemophilia ." He had several additional episodes of arteria l tears 
prior to his death 3 years late r. His m other had died at age 33 years 
of uterin e rup ture during labor with her third child. T hus, in two 
generations almost the fi.III spectrum of clinica l presentations were 
featured in this family but the rarity of the condition and mislead-
ing laboratory testi11 g delayed the identification of the correct 
diagnosis . 
M any issues still rema in abou t the treatment for this condition. 
T he genera.lized nature of the disorder and the involvem ent of 
ubiquitously expressed genes that ha ve dominantly acting muta-
tion s make "gene-based" therapy unlikely in the near future. 
Instead , pham1acologic therapy directed at increased degradation of 
abnoru1al mol ecules or "repair" of the damaged extracellul ar 
matrix seems th e most plausible approach for the near future . At 
this point no effective therapies exist that are known to decrease the 
rate of arteLial, bowel, o r uterine complications. Treatment remains 
symptomatic, and surgical repair is the main stay of therapy but is 
hampered by tissue friability. It is our impression that surge ry in 
younger people is less compl.icated than in older individuals. 
Removal of a LL or part of the colon m ay be an efi'ectivc deterent to 
bowel rupture, as the small intestin e is only rarely the site of such 
events. 
Type Ill procollagen is a member of the fibrillar collagen family 
aud has a core region triple helix that contains 1029 amino acids in 
w hich glycine is in every third position (i .e. , [Giy-X-Y)342). T his 
region is encoded by portions of 42 exons that carry casettes of 
codons for sequences that begin with a glyc ine and end with a 
Y -position amino acid , so that exon-skipp in g mutations leave the 
reading frame of the mR .. N A i11tact. T he mutations that give rise to 
EDS type IV are of several types: point mutations tbat result in 
substitution of single glycine residues within the triple helix, point 
mutations that (like the one described) alter spli ce junctions and 
lead to exon-skipping, small deletions that lead to loss of part or all 
of an exon-cncoded sequen ce in the triple helix, point mutations 
that lead to selection of cryptic splice sites and inclusion of new 
sequence derived from intron , and multi-cxon deletions. T he first 
two categories constitute the majority of all mutations described. 
Like all the exon-skipping mutations due to point mutations that 
have been described in the literature, the mutation described by 
Kuivanicmi and colleagues alters one nucleotide withi11 the con-
sensus spl.ice-donor sequence. T he reason for the predominance of 
donor site mutations is not clear. One possibility is that protein-
based screening for abnormali ties in type III procollagcn structure 
may favor the identifi cation of mutations that result in abnormal 
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chains. If acceptor site mutations lead to use of cryptic splice sites 
that change reading frame, the resultant mRNA with an interior 
termination codon could be unstable . As " null " alleles have not yer 
been identified among people with EDS type IV, it seems plausible 
that acceptor site mutations might preferentially resu lt in unstable 
mRNA products and thus not be detected by the routine screening 
that is don e. The phenotype of such mutations is not clear. Systemic 
aneurysms, in the absence of other features ofEDS type IV, do not 
seem to be derived from " null" mutations in the COL3Al gene, 
based on other studies from Kuivaniemi ef a/ [27) and Tromp e/ a/ 
[28], as cells from the vast majority of affected individuals expressed 
both COL3A 1 alleles and did not contain mutations in the 
COL3A 1 coding sequences . 
T he study of genetic disorders provides powerful toois in the 
analysis of the fun ction of genes and their encoded proteins. Given 
the already published studies of mutations in EDS type IV, we can 
be sure that type Ill procollagen is important for arterial, bowel 
wall, and uterine integrity. Put slightly differently, mutations of 
m any kinds in the COL3A 1 gene interfere with the structural 
integrity of these organs. Certain mutations give rise to marked 
alterations in collagen fibril structure, even though most of the 
macromolecules in these fibrils arc type I collagen . When fibrils are 
sm all, skin is very thin , suggesting that there is a role for the 
m olecul e in the initial modeling of skin. Mutations in the COL3A1 
gene and the synth esis of abnonnal type I[[ coHagen molecules 
clea.rly aJter many f.1 cets of fibrillogcnesis and tissue building, 
altho ugh we arc still at a loss to provide a comprehensive expla-
nation of the m echanisms. 
EDS type IV is only one of several varieties ofEDS. Because the 
molecular basis of these disorders is different and the clinical compli-
cations of each are di stinct, it is important tha t clini cal diagnosis is 
established by appropriate diagnostic studi es. UnfortUJlately, sev-
eral of the o lder texts fail to distinguish the complications of EDS 
type IV from those of other types of EDS. In some instances people 
expect the life-threatening complication of EDS type lV to affect 
individuals with other forms of EDS . T he paper from Kuivaniemi 
and coll eagues a.lso provides the important reminder that biochem-
ical and molecular studies of individuals with these unconunon 
genetic disorders can augm ent our understanding of basic biologic 
process such as mRNA splicing, macromolecular aggregation and 
secretion, and tissue patterning in the embryo. T hese are important 
lessons that should not. be forgotten. 
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